Growth hormone and prolactin responses to bolus and sustained infusions of GRH-1-40-OH in man
- PMID: 3119697
- DOI: 10.1007/BF03348157
Growth hormone and prolactin responses to bolus and sustained infusions of GRH-1-40-OH in man
Abstract
To determine whether GRH stimulates PRL secretion we studied the effects of iv bolus injections and prolonged infusions of GRH 1-40-OH on PRL and GH serum levels in normal volunteers. Eight patients with acromegaly, two of whom had elevated basal levels of PRL, were also tested with single bolus injections. Six normal subjects given 3.3 micrograms/kg bolus injections of GRH showed a mean increment of GH of 22.0 +/- 1.7 ng/ml (mean +/- SE). A small rise in PRL was noted in 5 of the 6 subjects (mean peak level of 6.4 +/- 1.9 ng/ml vs basal level of 3.3 +/- 0.4 ng/ml, p less than 0.05). During the continuous intusion of GRH (10 ng/kg/min), GH levels rose gradually from a mean baseline of 1.1 +/- 0.1 ng/ml to a mean peak of 30.0 +/- 7.2 ng/ml at about 2 h and then slowly declined to a nadir of 4.2 +/- 0.4 ng/ml at 330 min. PRL levels did not rise significantly during the infusion. To determine whether the decline in GH levels in the face of continued infusion was due to loss of GH responsiveness, a 3.3 micrograms/kg bolus of GRH was given during the nadir at 330 min; this GH increment was significantly less than that obtained by the GRH bolus injection without the infusion (12.9 +/- 3.5 ng/ml vs 22.0 +/- 1.7 ng/ml, p less than 0.05). The PRL response to the GRH bolus was the same during the infusion of GRH as before. In each of 8 acromegalic patients (including two who had initially elevated basal PRL levels) GRH led to an increase in both GH and PRL levels. PRL and GH levels spontaneously fluctuated in parallel in 4 acromegalic cases studied with repeated samples over 6 h during placebo administration. These experiments show that GRH has significant, though weak, PRF effect in normals and that it is more potent PRF in acromegalic patients. Furthermore, the effects on GH and PRL of a sustained infusion of GRH for 5 1/2 h are both qualitatively and quantitatively different. These results suggest that the GRH effect is exerted either on different pituitary receptors for GH and PRL regulation, or that the releasable pools of the two hormones have different sizes and/or turnover times.
Similar articles
-
Growth hormone-releasing hormone infusion in patients with active acromegaly.J Clin Endocrinol Metab. 1986 Jul;63(1):88-93. doi: 10.1210/jcem-63-1-88. J Clin Endocrinol Metab. 1986. PMID: 3086362
-
Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.J Clin Endocrinol Metab. 1986 Aug;63(2):475-80. doi: 10.1210/jcem-63-2-475. J Clin Endocrinol Metab. 1986. PMID: 3088026
-
Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.J Clin Endocrinol Metab. 1985 Jan;60(1):48-52. doi: 10.1210/jcem-60-1-48. J Clin Endocrinol Metab. 1985. PMID: 3917270
-
Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.J Clin Endocrinol Metab. 1990 Sep;71(3):585-90. doi: 10.1210/jcem-71-3-585. J Clin Endocrinol Metab. 1990. PMID: 2118536
-
Evidence-based definition of hypoprolactinemia in European men aged 40-86 years: the European male ageing study.Rev Endocr Metab Disord. 2024 Dec;25(6):1097-1107. doi: 10.1007/s11154-024-09890-0. Epub 2024 Jun 3. Rev Endocr Metab Disord. 2024. PMID: 38829475 Free PMC article. Review.
Cited by
-
Significance of growth hormone-releasing hormone receptor mRNA in non-neoplastic pituitary and pituitary adenomas: a study by RT-PCR and in situ hybridization.J Neurooncol. 1999 Feb;41(3):197-204. doi: 10.1023/a:1006151001536. J Neurooncol. 1999. PMID: 10359139
-
Prolactin response to growth hormone-releasing hormone during chronic thyrotropin-releasing hormone infusion in the treatment of amyotrophic lateral sclerosis.J Endocrinol Invest. 1990 Sep;13(8):631-6. doi: 10.1007/BF03349584. J Endocrinol Invest. 1990. PMID: 2125610
-
Ectopic acromegaly with tumoral range hyperprolactinemia and apoplexy with a dramatic regression of pituitary hyperplasia.Front Endocrinol (Lausanne). 2024 Oct 10;15:1473167. doi: 10.3389/fendo.2024.1473167. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39449742 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources